Ritonavir/Rifampin; Rifapentine
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may process your ritonavir more quickly.
What might happen:
Your blood levels of protease inhibitor may decrease and reduce its beneficial effects.
What you should do about this interaction:
Contact your healthcare professionals (e.g. doctor or pharmacist) as soon as possible about taking these two medicines together. They may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Norvir (ritonavir) US prescribing information. Abbott Laboratories November, 2012.
2.Priftin (rifapentine) US prescribing information. Sanofi-Aventis U.S. LLC July, 2010.
3.Centers for Disease Control and Prevention Division of Tuberculosis Elimination. Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors. Available at http://www.cdc.gov/nchstp/tb/tb_hiv_drugs/PDF/tbhiv.pdf January 20, 2004.
4.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.
